Physician profile
Paul H Wright
NPI 1932208758
$1,303.80
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $102 · 2021: $397 · 2022: $214 · 2023: $315 · 2024: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $795.29 | 2019-2024 | Linzess, Viberzi, Mavyret |
| Covidien Lp | $128.00 | 2019 | |
| Celgene Corporation | $100.81 | 2021-2023 | Zeposia |
| Evoke Pharma, INC. | $67.18 | 2021-2022 | |
| Iovance Biotherapeutics, INC. | $65.93 | 2024 | Amtagvi |
| Janssen Biotech, INC. | $52.44 | 2022-2024 | Stelara |
| Pfizer INC. | $36.34 | 2019-2023 | |
| Ironwood Pharmaceuticals, INC | $28.05 | 2020-2021 | |
| Alfasigma USA, INC. | $15.32 | 2020 | |
| Ferring Pharmaceuticals INC. | $14.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.